T. Rowe Price Associates
SION

T. Rowe Price Associates’s Sionna Therapeutics SION Stock Holding History

T. Rowe Price Associates’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.3M Sell
756,376
-74,997
-9% -$2.86M ﹤0.01% 927
2025
Q4 		$34.2M Buy
831,373
+193,613
+30% +$7.34M ﹤0.01% 928
2025
Q3 		$18.8M Sell
637,760
-223,478
-26% -$4.86M ﹤0.01% 1070
2025
Q2 		$14.9M Sell
861,238
-134,974
-14% -$1.77M ﹤0.01% 1030
2025
Q1 		$10.4M Buy
+996,212
New +$16.3M ﹤0.01% 1111

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's SION Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Sionna Therapeutics (SION) stake by 9% in Q1 2026, selling an estimated $2.86M and leaving 756,376 shares worth $30.3M. The position accounts for ﹤0.01% of the portfolio, ranked #927.

T. Rowe Price Associates first reported a position in SION in Q1 2025 and has held it in 5 quarters since. The position peaked at $34.2M in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • T. Rowe Price Associates held 756,376 shares of Sionna Therapeutics worth $30.3M as of Q1 2026.
  • T. Rowe Price Associates sold 74,997 Sionna Therapeutics shares in Q1 2026, an estimated $2.86M.
  • Sionna Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #927 holding.
  • T. Rowe Price Associates first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Sionna Therapeutics position peaked at $34.2M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.